Dec 16, 2021
Shareholder Newsletter December 2021

The Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) Shareholder Update – December 2021 is now available to view online.
In this issue:
>> VIRALEZE™ launches in Vietnam and Italy
>> VIRALEZE™ active against Delta and other SARS-CoV-2 variants; Omicron testing planned
>> Positive DEP® cabazitaxel phase 2 interim results in advanced prostate cancer
>> DEP® docetaxel | Phase 2 clinical program
>> DEP® irinotecan | Phase 2 clinical program
>> VIRALEZE™ protects against SARS-CoV-2 in challenge model
>> VIRALEZE™ registered in Saudi Arabia, Vietnam, and New Zealand
>> Fleurstat BVgel featured in Retail Pharmacy publication
>> AZD0466 featured at ASH Meeting
>> DEP® partnerships
>> Starpharma In the Media
>> Outlook
Download: Shareholder Update December 2021 (pdf file, 849kb)
This contains certain forward-looking statements.